- Home
- SMBK vs PHAT Comparison
SMBK vs PHAT Comparison
Compare SMBK & PHAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMBK
- PHAT
- Stock Information
- Founded
- SMBK N/A
- PHAT 2018
- Country
- SMBK United States
- PHAT United States
- Employees
- SMBK N/A
- PHAT N/A
- Industry
- SMBK Major Banks
- PHAT Biotechnology: Pharmaceutical Preparations
- Sector
- SMBK Finance
- PHAT Health Care
- Exchange
- SMBK Nasdaq
- PHAT Nasdaq
- Market Cap
- SMBK 553.9M
- PHAT 640.9M
- IPO Year
- SMBK N/A
- PHAT 2019
- Fundamental
- Price
- SMBK $33.23
- PHAT $8.35
- Analyst Decision
- SMBK Buy
- PHAT Strong Buy
- Analyst Count
- SMBK 4
- PHAT 5
- Target Price
- SMBK $37.25
- PHAT $16.40
- AVG Volume (30 Days)
- SMBK 55.9K
- PHAT 937.1K
- Earning Date
- SMBK 07-21-2025
- PHAT 08-07-2025
- Dividend Yield
- SMBK 0.96%
- PHAT N/A
- EPS Growth
- SMBK 62.51
- PHAT N/A
- EPS
- SMBK 2.47
- PHAT N/A
- Revenue
- SMBK $178,959,000.00
- PHAT $81,859,000.00
- Revenue This Year
- SMBK $22.41
- PHAT $195.03
- Revenue Next Year
- SMBK $10.59
- PHAT $106.77
- P/E Ratio
- SMBK $13.46
- PHAT N/A
- Revenue Growth
- SMBK 20.51
- PHAT 3055.70
- 52 Week Low
- SMBK $25.58
- PHAT $2.21
- 52 Week High
- SMBK $37.72
- PHAT $19.71
- Technical
- Relative Strength Index (RSI)
- SMBK 38.31
- PHAT 47.45
- Support Level
- SMBK $35.29
- PHAT $7.61
- Resistance Level
- SMBK $35.67
- PHAT $9.23
- Average True Range (ATR)
- SMBK 0.84
- PHAT 0.66
- MACD
- SMBK -0.38
- PHAT -0.08
- Stochastic Oscillator
- SMBK 0.74
- PHAT 30.64
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.